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Abstract: Drug-induced liver injury (DILI) has become a leading cause of severe liver disease in Western countries and 
therefore poses a major clinical and regulatory challenge. Whereas previously drug-specific pathways leading to initial in-
jury of liver cells were the main focus of mechanistic research and classifications, current concepts see these as initial up-
stream events and appreciate that subsequent common downstream pathways and their attenuation by drugs and other en-
vironmental and genetic factors also have a profound impact on the risk of an individual patient to develop overt liver dis-
ease. This review summarizes current mechanistic concepts of DILI in a 3-step model that limits its principle mechanisms 
to three main ways of initial injury, i.e. direct cell stress, direct mitochondrial impairment, and specific immune reactions. 
Subsequently, initial injury initiates further downstream events, i.e. direct and death receptor-mediated pathways leading 
to mitochondrial permeability transition, which then results in apoptotic or necrotic cell death. For all mechanisms, mito-
chondria play a central role in events leading to apoptotic vs. necrotic cell death. New treatment targets consequently fo-
cus on interference with downstream pathways that mediate injury and therefore determine the ultimate outcome of DILI. 
Genome wide and targeted pharmacogenetic as well as metabonomic approaches are now used in order to reach the key 
goals of a better understanding of mechanisms in hepatotoxicity, and to develop new strategies for its prediction and 
treatment. However, the complexity of interactions between genetic and environmental risk factors is considerable, and 
DILI therefore currently remains unpredictable for most hepatotoxins. 
Keywords: Acetaminophen, apoptosis, death receptors, drug-induced liver injury, drug metabolism, Fas, glutathione, hepato-
toxicity, metabonomics, mitochondria, mitochondrial permeability transition, necrosis, TNF alpha. 
INTRODUCTION 
The liver may be considered as the most important organ 
in drug toxicity for two reasons: on the one hand it is func-
tionally interposed between the site of absorption and the 
systemic circulation and is a major site of metabolism and 
elimination of foreign substances; but on the other hand 
these features also render it a preferred target for drug toxic-
ity. Drug-induced liver injury (DILI) therefore poses a major 
clinical problem. DILI has become the leading cause of acute 
liver failure and transplantation in Western countries [1, 2]. 
Intrinsic hepatotoxicity following acetaminophen (APAP; 
paracetamol in Europe) overdose accounts for the majority 
of cases of drug-induced acute liver failure in the United 
States and the United Kingdom. In contrast, hepatotoxicity 
associated with most other drugs is idiosyncratic, which im-
plies by definition that DILI develops in only a small propor-
tion of subjects exposed to a drug in therapeutic doses, and 
the risk of acute liver failure associated with idiosyncratic 
hepatotoxins is usually less than 1 per 10’000 exposed pa-
tients. However, more than 1’000 drugs and herbal products 
have been associated with idiosyncratic hepatotoxicity [3-6], 
and taken together idiosyncratic hepatotoxicity is responsible 
for more than 10% of all cases of acute liver failure [1, 2]. 
DILI also represents a major challenge for industry and regu-
latory authorities: it is a leading cause for termination of fur-
ther substance development in preclinical and clinical 
phases, and it is also the most common single adverse drug 
reaction leading to refusal of market approval. However, in 
many instances a drug’s hepatotoxic potential can only be 
recognized postmarketing, and DILI has therefore also been 
the most frequent single reason for withdrawing drugs from 
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the market and frequently requires modification of labeling 
[7, 8]. 
One of its most intriguing features is the fact that DILI 
can mimic all forms of acute or chronic liver disease. An-
other aspect of particular interest is the unpredictable idio-
syncratic occurrence of DILI and the chemical heterogeneity 
of hepatotoxins causing idiosyncratic DILI. These aspects 
already indicate the wide range of targeted structures and cell 
types, the diversity of the involved mechanisms, and the im-
portance of individual risk factors. During recent years the 
increasing insight into the complex processes and sequence 
of events involved in liver cell injury in general and DILI in 
particular had a substantial impact on current approaches to 
mechanistic hepatotoxicity and the subsequent definition of 
future research targets. Whereas previously drug-specific 
pathways leading to the initial injury of liver cells were the 
main focus of mechanistic research and classifications, cur-
rent concepts see these as so-called initial “upstream” events 
and appreciate that subsequent common “downstream” 
pathways and their activation or inhibition by drugs and 
other environmental and genetic factors also have a profound 
impact on the risk of an individual patient to develop overt 
liver disease. In particular, these concepts emphasize the 
central role of mitochondria, of events leading to apoptotic 
vs. necrotic cell death, and of factors that balance injurious 
vs. protective and regenerative responses towards initial cell 
stress. 
This review will therefore focus on these new concepts 
and their implication for our understanding of mechanisms 
and risk factors including their complex interactions, as well 
as for the development of new treatments in DILI. 
GENERAL MECHANISMS OF HEPATOTOXICITY 
DILI is commonly classified into intrinsic vs. idiosyn-
cratic hepatotoxicity, and the latter further into allergic vs. 3042    Current Medicinal Chemistry,  2009 Vol. 16, No. 23 Russmann et al. 
non-allergic. Intrinsic hepatotoxicity is regarded as dose-
dependent and predictable above an approximate threshold 
dose, whereas idiosyncratic hepatotoxicity occurs without 
obvious dose-dependency and in an unpredictable fashion. 
Allergic idiosyncratic hepatotoxicity is characterized by the 
presence of typical symptoms and signs of adaptive immune 
reactions, including fever, skin reactions, eosinophilia, for-
mation of autoantibodies, and a short latency time particu-
larly after re-exposure. Other clinical classifications differen-
tiate e.g. between hepatocellular, cholestatic or mixed liver 
enzyme patterns, histological criteria, acute vs. chronic on-
set, or severity. These classifications are useful in clinical 
practice because they describe typical clinical signatures of 
DILI for specific drugs, and they can also give useful hints 
regarding the involved mechanisms. Nevertheless, one must 
realize that these classifications are descriptive and based on 
clinical or histopathological criteria. They can therefore be 
misleading if mixed with mechanistic concepts and may in-
deed be the foundation of some classic paradigms that are 
now challenged by recent advances in mechanistic hepato-
toxicity. For example, common misconceptions are that spe-
cific substances can be clearly classified as either intrinsic or
idiosyncratic hepatotoxins, and that dose or direct cell injury 
play no role in idiosyncratic hepatotoxicity. However, un-
predictable rare severe DILI often develops on a background 
of frequent and dose-dependent mild increases in transa-
minases. Isoniazid is an example for such a hepatotoxin that 
is associated with mild intrinsic as well as severe idiosyn-
cratic occurrence of DILI. On the other hand APAP, consid-
ered as a classic intrinsic hepatotoxin in doses above 10 to 15 
g per day, may cause severe liver disease in therapeutic 
doses below 4 g per day in some patients [9, 10], whereas 
other patients tolerate very high doses without problems 
[11]. And even if no clear dose-response relationship can be 
established for drugs associated with idiosyncratic DILI, 
idiosyncratic hepatotoxicity is extremely rare for any drug in 
doses below 10 mg per day [12, 13], and allergic halothane-
induced hepatotoxicity occurs more frequently at higher 
doses [14]. 
A major challenge for mechanistic classifications is that 
DILI is not sufficiently characterized by the initial injury, but 
always involves several mechanisms, regulatory systems and 
risk factors with complex interactions; this also explains why 
for most hepatotoxins there are no experimental models 
available, a drug’s hepatotoxic potential is often not recog-
nized before marketing, the exact contribution of different 
processes leading to DILI in humans remain largely un-
known, and targeted treatments of DILI are not available 
except for APAP-induced hepatotoxicity. A possible ap-
proach to this dilemma is a general working model that inte-
grates the principle initial specific mechanisms of toxic liver 
cell injury with recently gained knowledge of the unspecific 
complex regulation of injurious vs. protective processes in-
volved in liver cell injury. 
A GENERAL 3-STEP MODEL FOR DRUG-INDUCED 
LIVER INJURY 
Such a general mechanistic model is presented in Fig. 
(1). According to this model DILI involves three subsequent 
main steps. It also includes details on the intrinsic and extrin-
sic pathways emphasizing the central role of mitochondria 
for the mechanisms leading to apoptosis vs. necrosis. Fig. (2)
additionally demonstrates the important role of risk factors in 
DILI. 
1. Initial Mechanisms of Toxicity: Direct Cell Stress, Di-
rect Mitochondrial Impairment, and Specific Immune 
Reactions 
First, drug metabolites or less frequently also parent 
drugs cause direct cell stress, target mitochondrial function, 
or trigger specific immune reactions. The most important 
drug metabolizing enzyme system for the creation of hepato-
toxic reactive metabolites is the polymorphic cytochrome 
P450 (CYP450) family that mediates oxidative phase-I drug 
metabolism. However, conjugative phase-II metabolism may 
also result in hepatotoxic metabolites, e.g. acyl glucuronides 
are well known to cause DILI [15, 16]. 
Reactive metabolites can exert initial cell stress through a 
wide range of mechanisms including depletion of glutathione 
(GSH), or binding to enzymes, lipids, nucleic acids and other 
cell structures. Furthermore reactive metabolites or parent 
drugs may specifically inhibit other hepatocellular functions 
such as the apical (canalicular) bile salt efflux pump (BSEP, 
ABCB11 gene), in which case the subsequent intracellular 
accumulation of its substrates may cause secondary toxic 
hepatocyte damage [17]. 
In case of initial targeting of mitochondria, reactive me-
tabolites or parent drugs uncouple or inhibit the mitochon-
drial respiratory chain causing ATP depletion and increased 
concentrations of reactive oxygen species (ROS), inhibit -
oxidation leading to steatosis (e.g. after intramitochondrial 
accumulation of amiodarone), damage mitochondrial DNA 
or interfere with its replication, or directly cause mitochon-
drial permeability transition (MPT), i.e. opening of the 
“MPT pore” located in their inner membrane [18-21]. There 
is probably an injury threshold that involves inhibition of 
mitochondrial electron transport below a critical threshold 
and an increase in cytosolic ROS and JNK activation above a 
critical threshold for liver injury to take place. The inhibition 
of mitochondrial electron transport in the early stages will 
not be reflected by elevated ALT values, indicating the re-
quirement for earlier markers of impending mitochondrial 
damage. Functional tests such as the 
13C-methionine breath 
test or the use of NMR spectra for metabonomics may prove 
to be useful here [22-24]. 
Specific immune responses involving cytotoxic T-cells 
with concomitant release of inflammatory cytokines can be 
evoked by reactive metabolites that covalently bind to pro-
teins and are subsequently recognized as neo-antigens (hap-
ten formation). Their subsequent major histocompatibility 
complex (MHC)-dependent presentation on antigen present-
ing cells may then activate formation of antibodies against 
haptens or autoantibodies against cell structures such as 
CYP450 enzymes [25, 26]. 
In some instances initial injury also targets nonparen-
chymal liver cells. Examples include toxicity against biliary 
epithelial cells by reactive flucloxacillin metabolites [27], 
direct activation of stellate cells by methotrexate leading to 
fibrosis [28], or sinusoidal toxicity by herbal pyrrolizidine Mechanisms of Hepatotoxicity  Current Medicinal Chemistry,  2009 Vol. 16, No. 23      3043
Fig. (1). A 3-step mechanistic working model of hepatotoxicity. First, initial injury is exerted through direct cell stress, direct mitochondrial 
inhibition and/or specific immune reactions. Second, initial injury can lead to mitochondrial permeability transition (MPT). Direct cell stress 
causes MPT via the intrinsic pathway. The intrinsic pathway involves activation of intracellular stressor cascades and pro-apoptotic proteins 
including Bax. Alternatively MPT can be initiated through the death receptor-mediated extrinsic pathway that is activated by immune reac-
tions and/or after sensitization to TNF and FasL binding to death receptors. Cytokines modulate the sensitivity of its activation. Third, MPT 
leads to necrosis or apoptosis depending on the availability of ATP. In hepatocytes activation of initiator caspase 8 through the extrinsic 
pathway is not sufficient to directly activate apoptosis, but amplification through pro-apoptotic factors including Bid and ceramides lead to 
MPT, which will then lead to the apoptotic pathway that is activated in the presence of sufficient remaining ATP production. Necrosis occurs 
if there is no ATP available, which is required for energy-consuming apoptotic pathways. Several highlighted amplification mechanisms (A) 
may play an important role at different levels for the idiosyncratic occurrence of hepatotoxicity. 3044    Current Medicinal Chemistry,  2009 Vol. 16, No. 23 Russmann et al. 
Fig. (2). Risk factors for hepatotoxicity. First, risk factors can be classified into environmental vs. genetic factors. From a mechanistic point 
of view risk factors can further affect all different levels of events leading to the final outcome of drug-induced liver injury, which is mostly 
dichotomous, i.e. full recovery vs. acute liver failure. Note that risk factors affecting events downstream of initial injury are rather unspecific 
regarding different hepatotoxins. The figure presents a selection of well-described risk factors, but one must assume that other factors also 
play a role, of which many currently remain unknown.Mechanisms of Hepatotoxicity  Current Medicinal Chemistry,  2009 Vol. 16, No. 23      3045
alkaloids or chemotherapy used for hematopoietic stem cell 
transplantation causing sinusoidal obstruction syndrome 
(venoocclusive disease) [29]. Further discussion of such 
nonparenchymal hepatotoxicity is beyond the scope of this 
review, but if the resulting damage is sufficiently severe it 
may eventually also extend to hepatocytes and lead to acute 
or chronic liver failure. 
Different hepatotoxins are typically associated with spe-
cific patterns regarding their initial mechanism of injury. 
However, one should be aware of the fact that a single drug 
may concomitantly act through several of these initial 
mechanisms, and that for many drugs at least some of the 
involved mechanisms currently remain unknown. 
These initial specific injurious mechanisms can also be 
referred to as “upstream events”. In the next step they lead to 
subsequent rather unspecific “downstream events” that in-
volve the innate immune system, which balances pro- and 
anti-inflammatory responses and therefore determines the 
further progress to severe injury or recovery.  
2. Direct and Death Receptor-Mediated Pathways Lead-
ing to Mitochondrial Permeability Transition 
Second, initial cell stress and/or initial specific immune 
reactions lead to MPT. If the initial mechanism does not di-
rectly target and impair mitochondrial function, this occurs 
in two principle ways, i.e. either via a direct pathway initi-
ated by severe cell stress (intrinsic pathway), or via an indi-
rect death receptor-amplified pathway that is triggered by 
mild cell stress and/or specific immune reactions (extrinsic 
pathway) [30]. 
In the intrinsic pathway severe intracellular stress acti-
vates the endoplasmic reticulum pathway, lysosomal perme-
abilization, or c-jun N-terminal kinase (JNK) [31-34]. Sub-
sequent activation of pro-apoptotic (e.g. Bax, Bak, Bad) and 
inhibition of anti-apoptotic (e.g. Bcl-2, Bcl-xL) proteins of 
the Bcl-2 family then activates MPT. 
In the extrinsic pathway an initial mild injury may be 
amplified if inflammatory responses due to mild stress 
and/or additional factors have modulated the innate immune 
system, where signaling cytokines that promote (e.g. IL-12) 
or prevent (e.g. IL-4, IL-10, IL-13, MCP-1) injury are usu-
ally well balanced. As a consequence, sensitized liver cells 
become more susceptible to lethal effects of tumor necrosis 
factor alpha (TNF), Fas ligand (FasL) and interferon 
gamma (IF). This is particularly important if one considers 
that the liver as the central organ of detoxification is con-
stantly exposed to cell stress that can activate TNF and 
FasL. If the initial event is a specific immune reaction, 
MHC-dependent antigen presentation will activate the re-
lease of TNF and FasL from Kupffer cells (hepatic macro-
phages) and cytotoxic T-cells. According to the danger hy-
pothesis for autoimmune diseases, haptenization alone may 
be insufficient to trigger the development of frank allergic 
hepatotoxicity, which requires an additional stimulation, a 
so-called danger-signal [12]. If reactive metabolites cause 
concomitant mild direct cell stress or if other concomitant 
inflammatory diseases are present, the accompanying release 
of injurious cytokines may constitute such a danger signal 
that promotes MHCII-dependent antigen presentation, ren-
ders hepatocytes more susceptible to injury, and therefore 
promotes autoimmune hepatotoxicity. Regardless of how the 
extrinsic pathway is initiated, eventually TNF and FasL 
bind to intracellular death receptors, and TNF and Fas recep-
tor-associated death domain proteins (TRADD/FADD) will 
subsequently activate initiator caspase 8. The activating 
death-receptor complex is also called the death-inducing 
signaling complex (DISC). Although initiator caspase 8 can 
start apoptosis through a direct activation of effector 
caspases 3, 6 and 7, this direct path appears to be too weak in 
hepatocytes to mediate apoptosis [35]. Therefore an amplifi-
cation mechanism is required: caspase 8 can activate pro-
apoptotic Bcl-2 proteins (e.g. Bid), as well as signaling ce-
ramides. Like in the intrinsic pathway this leads to MPT, 
which therefore plays a key role and is a common step that 
mediates further cell death in both, intrinsic as well as extrin-
sic pathways [36]. 
3. Apoptosis and Necrosis 
Third, impaired mitochondrial function and energy pro-
duction leads to apoptotic or necrotic cell death. MPT allows 
massive influx of protons through the inner mitochondrial 
membrane, which stops mitochondrial ATP synthesis. Mito-
chondrial ATP depletion resulting from MPT (or other direct 
mechanisms of mitochondrial damage mentioned above) 
causes matrix expansion and mitochondrial outer membrane 
permeabilization and rupture with release of cytochrome c 
and other pro-apoptotic mitochondrial proteins from the in-
termembrane space into the cytosol [30, 37-39]. 
In the case of apoptosis, cytochrome C then binds to a 
cytoplasmic scaffold (apaf-1) and pro-caspase 9, forming a 
complex called apoptosome, which activates signaling pro-
caspase 9. This, however, is an active process that requires 
ATP and can therefore only start if MPT did not rapidly and 
simultaneously occur in all mitochondria. Only if some mi-
tochondria are left intact and continue to synthesize ATP, 
activated pro-caspase 9 and possibly also other pro-apoptotic 
mitochondrial proteins subsequently activate executioner 
caspase 3. Caspase 3 will then cleave specific cell proteins 
and further activate pro-caspases 6,7 and 2, which have their 
own target proteins [40]. These processes eventually result in 
programmed apoptotic cell death, which is characterized by 
cytoplasmic and nuclear condensation and fragmentation 
without loss of membrane integrity. Histologically these re-
maining fragments are referred to as Councilman bodies. 
Apoptosis equals a “silent” cell death, where apoptotic frag-
ments are removed by phagocytosis with little accompanying 
inflammation and therefore also only little secondary dam-
age. 
Necrosis, in contrast, develops if the initial injury is so 
severe that MPT quickly occurs in all mitochondria, or if 
other mechanisms cause rapid severe mitochondrial ATP 
depletion, preventing the apoptotic pathway. This is typical 
for hepatotoxins that directly cause profound initial cell 
stress. However, in the absence of ATP also activation of the 
extrinsic pathway may lead to necrotic cell death. Cell swel-
ling and lysis that follow severe disturbance of cell functions 
characterize necrosis. Necrotic cell lysis induces inflamma-
tory responses including release of cytokines, which is im-
portant because these may amplify initial injury through a 3046    Current Medicinal Chemistry,  2009 Vol. 16, No. 23 Russmann et al. 
sensitization of surrounding hepatocytes and therefore cause 
further collateral damage. 
Finally it should be mentioned that the distinction be-
tween apoptosis and necrosis is not always clear-cut. Mixed 
phenomena have been described, and the same hepatotoxin 
may cause one or the other, or even the concomitant occur-
rence of both, depending on the circumstances including 
dose and preexisting vulnerability of hepatocytes [41, 42]. 
Apoptosis and necrosis may therefore also be regarded as a 
continuous spectrum. Furthermore some controversy exists 
around the exact mechanisms and triggers for hepatotoxic 
apoptosis including the role of MPT. 
In conclusion one can state that mitochondria stand in the 
center of life and death in hepatotoxicity: they can be targets 
of initial direct toxicity, MPT plays a key role in the further 
signaling of extrinsic and intrinsic pathways, and because 
mitochondria generate most of the cell’s ATP supply and are 
also the main intracellular source of oxygen and nitrogen 
free radicals, the extent of mitochondrial impairment finally 
determines whether hepatocytes die by apoptosis or necrosis 
[43]. 
Protective Mechanisms and Regeneration 
Additional factors and pathways modulate intrinsic and 
extrinsic pathways and the subsequent induction of apoptosis 
and necrosis. In addition to its DISC-mediated injurious ef-
fects, TNF on the other hand also induces nuclear transcrip-
tion factor kappa B (NF-B)-dependent survival gene ex-
pression. NF-B responsive genes inhibit JNK and promote 
upregulation of antioxidant genes [44]. Similarly, in response 
to oxidative stress nuclear factor erythroid-derived 2-like 
(NFE2L, also called Nrf2) upregulates antioxidant genes that 
protect against cell stress [45]. Particularly, the antioxidant 
glutathione (GSH) plays a key role for cell protection against 
DILI. GSH is an important scavenger of ROS of various 
origins in mitochondria and cytosol, but also of reactive me-
tabolites, e.g. N-acetyl-p-benzoquinone imine (NAPQI), the 
toxic metabolite of APAP formed by CYP450 2E1. Accord-
ingly, replenishment of GSH stores is the principle protective 
mechanism for treatment of APAP-intoxication with the 
GSH precursor N-acetylcysteine. Furthermore GSH appears 
to indirectly modify cell injury through an effect on other 
injurious or protective mechanisms, such as the requirement 
of high GSH levels for NF-B-activated survival gene ex-
pression [46, 47], or protection against Fas-induced apopto-
sis [48]. As mentioned above, also the innate immune sys-
tem, particularly natural killer T-cells, can have both, injuri-
ous as well as protective functions [49], and attenuation of 
Fas-induced hepatocyte injury by anti-inflammatory agents 
underlines the role of inflammatory responses for DILI [50]. 
Because of the liver’s extraordinary capacities to regen-
erate, full recovery is even possible if severe DILI has al-
ready caused extensive hepatocyte death [51]. Different 
models of hepatotoxicity using a variety of hepatotoxins 
have demonstrated the crucial dynamic role of mitotic hepa-
tocyte regeneration in response to toxic injury [52, 53]. The 
complex processes that promote hepatic tissue repair gener-
ally appear to show a dose-response relationship where 
stimulation of repair increases with higher exposure to hepa-
totoxins. However, above certain threshold toxicity also re-
generative processes may be inhibited, and many factors 
modulate this critical switch from regeneration to unopposed 
injury, which determines the final outcome in DILI [54-56]. 
Mitochondrial GSH content appears to be such a modulating 
factor, underlining once more the key role of mitochondria in 
DILI [57, 58]. Although DILI can lead to chronic liver dam-
age through special mechanisms such as chronic stimulation 
of fibrosis or targeted biliary toxicity with subsequent devel-
opment of vanishing bile duct syndrome [59], the outcome of 
DILI is therefore mostly dichotomous, i.e. acute liver failure 
vs. full recovery. 
Strengths and Limitations of the 3-Step Model 
The 3-step model represents an attractive approach to he-
patotoxicity for several reasons. An important feature is that 
it truly focuses on mechanisms and does not blend them with 
descriptive classifications, which eliminates some apparent 
contradictions that exist from other viewpoints. The model 
limits the principle mechanisms of DILI to three main ways 
of initial injury and on a vertical axis to three sequential 
main steps that lead to cell death. But at the same time it also 
integrates the crucial role of risk factors by appreciating the 
complex interactions of a large number of modulating factors 
and the fragile balance between injurious and protective fac-
tors that occur on all levels of the vertical axis (vide infra 
and Fig. (2)). In particular it emphasizes the importance of 
several amplification pathways and provides a plausible ex-
planation for the rare idiosyncratic occurrence of severe 
DILI that develops on a background of frequent mild liver 
injury. In the absence of cofactors such mild injury may be 
necessary though not sufficient to cause severe DILI. But in 
the presence of cofactors mild injury can be amplified and 
then tip the balance of injurious vs. protective processes to-
ward death pathways. This triggering role of cofactors is also 
able to plausibly explain the very long latency time that has 
been reported in some cases of DILI [60]. Furthermore, ap-
preciation of the crucial role of downstream events determin-
ing the final outcome of DILI has two important implications 
for the definition of research targets in hepatotoxicity. First, 
agents that typically cause intrinsic DILI (e.g. APAP) can be 
used for the study of common downstream mechanisms that 
may also be relevant for idiosyncratic hepatotoxicity [61]. 
Second, downstream events represent potential targets for 
the development of new treatments that aim to interrupt 
pathways leading to apoptosis or necrosis. 
At the same time any model is just a limited simplifica-
tion of complex reality. Also the 3-step model should there-
fore be considered as a guiding working model that has limi-
tations and may require adjustments to account for the ever-
growing knowledge in mechanistic hepatotoxicity. Consider-
ing the complexity and interactions of the large number of 
often species-specific injurious vs. protective processes in-
cluding metabolism, immune reactions and regeneration, a 
general concern is the extrapolation of data from animal or 
in-vitro models to humans. Demonstration of hepatotoxic 
mechanisms in such models does not necessarily imply that 
these also play a key role in human cases of DILI, particu-
larly if concentrations of toxicants used in models do not 
reflect conditions in humans. Furthermore, although the 
model a priori suggests that its 3 vertical steps occur con-
secutively, one should be aware of the possibility that drugs Mechanisms of Hepatotoxicity  Current Medicinal Chemistry,  2009 Vol. 16, No. 23      3047
may also directly affect downstream events. For example 
NAPQI has recently been shown to directly activate the 
Keap1-Nrf2 cell defense system [62-64]. Similarly, it may 
also be possible that drugs or their metabolites could directly 
stimulate other key elements in downstream pathways in-
cluding death receptors.  
A MECHANISTIC VIEW ON RISK FACTORS 
From a mechanistic point of view risk factors for hepato-
toxicity are of particular interest, because they are the very 
explanation for the rare occurrence that defines idiosyncratic 
DILI. Severe idiosyncratic DILI typically occurs in less than 
1 in 10’000 exposed patients, whereas most risk factors that 
have been associated with DILI have a much higher preva-
lence in the exposed population. In particular this is true for 
genetic polymorphisms, which, by definition, have a preva-
lence of at least 1%. Furthermore, even statistically signifi-
cant relative risk estimates for such associations tend to be 
weak and therefore do not allow a reliable prediction of DILI 
in clinical practice. In perfect accordance with a complex 
multi-step mechanistic model of hepatotoxicity, this indi-
cates that the presence of one single risk factor is usually not 
sufficient to explain the occurrence of idiosyncratic DILI, 
but that complex interactions of different mechanisms with 
several risk factors must be assumed in most cases. As men-
tioned above, incident environmental factors can function as 
triggering risk factors for DILI, particularly if they tip the 
balance of injurious vs. protective processes in the presence 
of other prevalent risk factors. 
Several clinical risk factors for DILI such as high age, 
female gender and concomitant diseases or drugs have been 
described. Many of those may actually be associated with 
altered pharmacokinetics, which are an obvious risk factor 
whenever toxicity is dose-dependent and altered pharma-
cokinetics result in elevated concentrations of parent drugs 
and/or their toxic metabolites. However, from a current 
mechanistic point of view, it is most interesting to ask where 
risk factors exert their effect based on a multi-step model of 
hepatotoxicity that differentiates specific upstream vs. non-
specific downstream mechanisms. In addition, risk factors 
can also be classified as either genetic or environmental. 
Such a view on risk factors superimposed on the 3-step 
model is shown in Fig. (2). 
An intriguing implication of this view is that patients 
with risk factors that attenuate rather unspecific downstream 
events may have increased susceptibility to several hepato-
toxins, and vice versa that common downstream risk factors 
could theoretically be identified in case-control studies that 
include idiosyncratic DILI cases caused by different hepato-
toxins. Another interesting implication is that DILI could be 
caused by a different constellation of mechanisms and risk 
factors with different manifestations in different subjects. 
For example, a drug may be metabolized via CYP450 into a 
reactive metabolite with mild toxicity on mitochondria and 
also have some inhibitory effects on excretion of bile acids, 
resulting in a mild increase of liver enzymes in a given pa-
tient. Environmental factors such as a newly introduced con-
comitant drug or also ethanol may now induce CYP450. The 
toxicity of the metabolite then results in the death of a criti-
cal number of hepatocytes with a subsequent immune reac-
tion against the reactive metabolite bound to hepatocyte pro-
teins, and the patient develops severe DILI with symptoms 
and signs of an immune reaction. In another patient taking 
the same drug, a genetic variation of hepatic transporters 
plus preexisting impaired mitochondrial function associated 
with high age may be sufficient to lead to clinical manifesta-
tion of icteric liver disease. 
Findings on idiosyncratic hepatotoxicity associated with 
herbal products containing kava (piper methysticum) may 
indeed be in accordance with this theoretical concept: several 
cases of acute liver failure during kava intake showed symp-
toms and signs of hypersensitivity indicating a specific im-
mune reaction [65, 66]; at the same time there appears to be 
a background of more frequent increases in transaminases 
[67], and there is also evidence for a direct inhibition and 
uncoupling of mitochondrial respiratory chain and induction 
of apoptosis [68]. 
The complex role of different mechanisms and risk fac-
tors in hepatotoxicity can also be demonstrated by the exam-
ple of APAP. APAP is a “classic” hepatotoxin for which an 
animal model is available, and also clinical APAP-induced 
DILI has been studied extensively. Toxification of APAP 
involves metabolism via CYP450 2E1, leading to its reactive 
metabolite NAPQI that causes oxidative cell stress unless it 
is detoxified by GSH. Once GSH stores are depleted cova-
lent binding to proteins occurs. This was long considered as 
the principle direct and sufficient hepatotoxic mechanism. 
Several risk factors that relate to APAP metabolism and 
NAPQI-induced oxidative stress were consequently identi-
fied: ethanol can induce but also competitively inhibit the 
formation of NAPQI via CYP450 2E1 [10], ethanol or also 
starvation may contribute to critical GSH depletion [69, 70], 
inhibition of the constitutive androstane receptor (CAR) that 
regulates APAP metabolism including the formation of 
NAPQI can abrogate APAP-induced hepatotoxicity [71], and 
activation of NFE2L, a master regulator system for antioxi-
dant defense that appears to be polymorphic in humans, pro-
tects against APAP toxicity [45, 72, 73]. However, recent 
research focused on further downstream events, and subse-
quently demonstrated that these also play a key role in APAP 
hepatotoxicity. Several studies showed that JNK, TNF,
IFN, FasL, IL10 and IL6 have a major impact on the final 
outcome following the formation of NAPQI and consump-
tion of GSH [31-33, 74-78]. Furthermore, several studies 
suggest that GSH also plays an important role in the regula-
tion of downstream events: GSH depletion appears to in-
crease injury in models of TNF-induced liver cell injury 
[47, 70, 79]. The mechanisms are not entirely clear but may 
involve increased activation of stress kinases, decreased de-
fense against mitochondrial oxidative stress, or inhibition of 
TNF-induced NF-B activation [80]. Furthermore, ethanol 
may also have a role in APAP-induced DILI through an im-
pairment of mitochondrial function [81], and after a potential 
role of transport proteins in DILI was realized, also hepato-
biliary efflux transporters were shown to affect APAP-
induced hepatotoxicity [82]. 
Studies of APAP-induced hepatotoxicity clearly demon-
strate the role of many environmental risk factors and the 
role of toxic metabolites, oxidative stress and defense against 
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initial toxic cell stress, as well as subsequent downstream 
events, for DILI. The relevance of other risk factors, particu-
larly genetic factors, has been shown with hepatotoxins that 
typically cause idiosyncratic hepatotoxicity. Like environ-
mental factors, genetic variations can principally affect all 
mechanisms involved in DILI, from drug metabolism over 
initial injury and mitochondrial impairment, to cell death and 
regeneration. 
Examples of genetic factors that affect drug metabolism 
or detoxification and have been associated with an increased 
risk of DILI are genetic variations in the GSH S-transferases 
GSTT1 and GSTM1, CYP450 2E1, N-acetyltransferase, as 
well as manganese superoxide dismutase (SOD2) [83-86]. 
Interestingly SOD2 resides in mitochondria, and troglitazone 
toxicity has been investigated in a SOD2+/- mouse model 
[87]. DILI occurring with hypersensitivity has also been as-
sociated with genetic polymorphisms that involve drug toxi-
fication or detoxification, which also suggests that dose plays 
a role in immune-mediated DILI [88, 89]. This is further 
supported by a correlation between quantitative differences 
in the metabolic toxification of different inhalational anes-
thetics and their associated risk for development of autoim-
mune hepatotoxicity [90]. HLA genotype variations have 
also been associated with allergic hepatotoxicity [91], al-
though their predictive value does not appear to be as high as 
for HLA variations linked to abacavir-induced hypersensitiv-
ity reactions [92, 93]. 
Cytokine polymorphisms associated with diclofenac-
induced hepatotoxicity are another genetic risk factor of par-
ticular interest, because they relate to a downstream mecha-
nism in DILI and could therefore also be relevant for other 
idiosyncratic hepatotoxins [94]. The same would apply to 
genetic variations involving mitochondrial function, and 
interestingly genetic deficiency of mitochondrial long-chain 
3-hydroxyacyl-CoA dehydrogenase has been associated with 
acute fatty liver of pregnancy, which is presumably related to 
increased levels of female sex hormones [95, 96]. However 
the relevance of this very rare variation for hepatotoxicity 
associated with estrogens or other drugs that inhibit mito-
chondrial -oxidation such as amiodarone is unclear. How-
ever, genetic mitochondrial abnormalities with subsequently 
increased susceptibility to hepatotoxins may also be age-
related and therefore be a possible explanation of increased 
risk of DILI with higher age [97-99]. Another environmental 
risk factor for DILI that acts via an impairment of mitochon-
drial function could be obesity and diabetes associated with 
steatosis and steatohepatitis [100-103]. 
Other genetic risk factors that recently gained much at-
tention are determinants of hepatic transport proteins. Ge-
netic (or environmental) factors that affect basolateral (sinu-
soidal) or apical (canalicular) transport systems will deter-
mine exposure of hepatocytes not only to toxic drugs but 
also to toxic bile constituents and therefore represent both, 
risk factors as well as mechanisms for cholestatic DILI [17, 
104-108]. Involvement of hepatic transporters has been re-
ported in DILI induced by troglitazone, hormonal contracep-
tives, or bosentan [106, 108-110]. For example, the V444A 
polymorphism in the BSEP (ABCB11) gene has been associ-
ated with an increased risk of DILI [107, 111], which may 
even affect drugs that do not typically cause a cholestatic 
pattern of injury. Furthermore, recently also variations in 
nuclear receptors PXR and CAR which not only regulate 
hepatic drug metabolism and disposition but also recognize 
bile acids have been identified and these may also modulate 
the risk for DILI with or without involvement of bile-acid 
induced injury [112].  
Considering the important role of inflammatory media-
tors that can sensitize hepatocytes to injurious effects to cy-
tokines (vide supra), it is not surprising that inflammation 
has not only been shown to enhance hepatotoxicity in an 
animal model [113], but also that a number of concomitant 
infectious diseases have been identified as clinical risk fac-
tors for DILI. Aspirin-induced liver failure in children with 
an inhibition of mitochondrial -oxidation in the presence of 
infection (Reye syndrome) is a well-known example [114, 
115]. But also patients undergoing antiretroviral treatment 
for HIV infection have a higher risk of severe hepatotoxicity 
when co-infected with the hepatitis B or C viruses, particu-
larly if the regimen contains protease inhibitors [116, 117] 
FUTURE PERSPECTIVES 
A better understanding of mechanisms of hepatotoxicity 
is a major future challenge in order to develop new solutions 
for the prevention and treatment of DILI. Recent important 
advances in the understanding of general hepatotoxic 
mechanisms are the foundation for further studies on mecha-
nisms for specific hepatotoxic drugs. The increased apprecia-
tion of the crucial role and complex regulation of down-
stream events that modulate the critical switch from recovery 
to unopposed injury also implies that they represent promis-
ing new therapeutic targets. For example, specific JNK in-
hibitors are in clinical development for the treatment of 
APAP-induced hepatotoxicity, and they could also be protec-
tive against other hepatotoxins. Other potential downstream 
targets are the inhibition of any amplifying pathways, e.g. 
through an inhibition of injurious or a stimulation of protec-
tive cytokines and Bcl-2 proteins. Also specific caspase in-
hibitors that may prevent apoptosis are a possible approach. 
Given that apoptosis activates stellate cells leading to liver 
fibrosis, attenuation of apoptosis may even lead to the reso-
lution of fibrosis. In fact, according to some reports, the 
beneficial effects of ursodeoxycholic acid are partly medi-
ated through an inhibition of apoptosis by modulating MPT 
[118, 119]. Nevertheless, one should be aware that apoptosis 
is not necessarily an unwanted mode of cell death as it is 
associated with little collateral damage. A new therapeutic 
approach that aims to inhibit apoptosis may therefore theo-
retically also result in a shift towards necrosis with additional 
collateral damage. Also the recently gained knowledge that 
GSH has a protective role not only via its action on upstream 
events, such as the prevention of NAPQI-induced initial in-
jury, but also via its effect on downstream processes that are 
not specific to APAP toxicity may justify trials that evaluate 
possible beneficial effects in the treatment of other forms of 
DILI including idiosyncratic hepatotoxicity. 
Knowledge of genetic and environmental contributors 
that determine actual idiosyncratic DILI in humans is neces-
sary in order to focus mechanistic in-vitro and animal toxi-
cology studies. Likewise, also prevention of DILI in clinical 
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tors that predict severe DILI with sufficient sensitivity and 
specificity. Pharmacogenetic approaches such as case-
control studies that consider interactions between genetic but 
also environmental factors may be able to reach that goal. 
However, the complexity of interactions being sufficient to 
cause severe DILI, the difficulties in the reliable identifica-
tion of environmental risk factors, and also in the reliable 
causality assessment of clinical cases of DILI must not be 
underestimated. Therefore it is currently unknown whether 
this is a realistic scenario for clinically important hepatotox-
ins. 
Considering the importance of hepatotoxic metabolites, 
strategies aimed at identifying early markers of DILI that 
may precede ALT elevations are focusing on the use of me-
tabonomics, e.g. high resolution NMR of urine samples. Pa-
tients that go to develop elevated ALT levels may have a 
different metabolome, and the spectra obtained before ALT 
values exceed the upper limit of normal might indicate a 
predictive metabolome signature. In fact, trials conducted 
with known idiosyncratic hepatotoxins such as isoniazid 
could be used to identify “Hy’s law” cases in serial collec-
tions [120, 121], allowing for metabonomics in well charac-
terized cases. 
Identification of risk factors for rare idiosyncratic hepato-
toxicity requires special networks that contribute to data col-
lection and subsequent identification of environmental as 
well as genetic risk factors for clinical cases of idiosyncratic 
DILI. With that in mind the DILI network project links sev-
eral university medical centers that collect detailed informa-
tion on cases of DILI including standardized causality as-
sessments and samples for genetic analyses. The data collec-
tion focuses on idiosyncratic hepatotoxicity and particularly 
aims to identify upstream as well as downstream genetic 
determinants of hepatotoxicity [122, 123]. Furthermore, the 
recognition that even very rare idiosyncratic DILI typically 
occurs on a background of more frequent mild increases in 
transaminases makes it possible to identify necessary (al-
though not sufficient) risk factors in controlled cohorts from 
prospective clinical trials. Genome wide association studies 
that analyze several hundred thousand single nucleotide po-
lymorphisms (SNPs) per patient have now become techni-
cally and economically feasible and have been successfully 
used for the identification of genetic risk factors even of rare 
adverse drug reactions in large phase III clinical trials [124]. 
Given the economical and regulatory pressure associated 
with severe idiosyncratic hepatotoxicity that is only identi-
fied after marketing of a new drug, such pharmacogenomic 
approaches will likely also be used for the identification of 
risk factors associated with DILI during clinical drug devel-
opment. 
From a clinical standpoint the important role of triggers 
and risk factors that may be required in idiosyncratic hepato-
toxicity should stimulate clinicians to search for such factors 
when collecting, analyzing and reporting data of individual 
cases and case series of DILI. Furthermore, the increasing 
recognition of the hepatotoxic potential of herbal products 
should alert physicians as well as consumers. In fact it is 
well possible that a substantial proportion of cases of so-
called “idiopathic” acute liver failure are indeed due to 
herbal hepatotoxicity. Every clinician should therefore in-
clude herbal products of any kind in the differential diagno-
sis and actively search for them when taking the history of a 
patient with liver disease of unclear origin. From a regula-
tory point of view the issue of herbal hepatotoxicity also 
raises the question whether not only herbal drugs but also 
herbal dietary supplements may generally require a stricter 
regulation of their distribution and use [4-6]. For diagnostic 
purposes it is also of interest that the recognition of apoptosis 
as an important mode of cell death in DILI implies that new 
markers for apoptosis such as the monoclonal M30 antibody, 
which recognizes a caspase-generated cytokeratin 18 neoan-
tigen, may be useful in the early diagnosis of DILI [125, 
126]. Nevertheless, DILI currently remains unpredictable for 
most hepatotoxins, and given that APAP is the only hepato-
toxin for which there is a proven therapy for the prevention 
of DILI available, every clinician should be reminded to 
avoid unnecessary drug use and to stop suspicious drugs 
immediately as soon as symptoms and signs of DILI are 
identified. 
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ABBREVIATIONS 
APAP =  Acetaminophen 
ATP =  Adenosine  triphosphate 
BSEP  =  Bile salt efflux pump 
CYP450 =  Cytochrome  P450 
DILI  =  Drug-induced liver injury 
DISC  =  Death-inducing signaling complex 
GSH =  Glutathione 
GST =    Glutathione  S-transferase 
IF =  Interferon 
IL =  Interleukin 
JNK  =  C-jun N-terminal kinase 
MHC  =  Major histocompatibility complex 
MPT  =  Mitochondrial permeability transition  
    (opening of the “MPT pore” in the inner 
mitochondrial membrane)  
NAPQI =  N-acetyl-p-benzoquinone  imine 
NF-B  =  Nuclear transcription factor kappa B 
NFE2L (Nrf2)  =  Nuclear factor erythroid-derived 2-like 
ROS  =  Reactive oxygen species 
SOD2  =  Manganese superoxide dismutase 
TNF  =  Tumor necrosis factor alpha 3050    Current Medicinal Chemistry,  2009 Vol. 16, No. 23 Russmann et al. 
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